<DOC>
	<DOCNO>NCT00490958</DOCNO>
	<brief_summary>Background : In haemodialysis patient , chronic heart failure ( CHF ) responsible high mortality rate , presently , little data available regard population . Aim study : Aim study determine whether telmisartan decrease all-cause cardiovascular mortality morbidity haemodialysis patient CHF impair leave ventricular ejection fraction ( LVEF ) add standard therapy ACE inhibitor . Methods : A 3-year randomized , double-blind , placebo-controlled , multicentre trial perform involve 30 Italian clinic . Haemodialysis patient CHF ( NYHA class II III ; LVEF 40 % ) randomize telmisartan placebo addition ACE inhibitor therapy . 332 patient enrol ( 165 telmisartan , 167 placebo ) , drug dosage titrate target dose telmisartan 80 mg placebo . Mean follow-up period 35Â±5 month . Primary outcome all-cause mortality , cardiovascular mortality CHF hospitalization .</brief_summary>
	<brief_title>Telmisartan Haemodialysis Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Adult haemodialysis patient CHF ; New York Heart Association ( NYHA ) class II III ; Ejection fraction less equal 40 % determine within 6 month ; Therapy ACE inhibitor individually optimize unchanged 30 day randomization Hypotension dialysis ; Atrial fibrillation ; Intolerant low dose telmisartan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>heart Failure</keyword>
	<keyword>haemodialysis</keyword>
	<keyword>telmisartan</keyword>
	<keyword>angiotensin convert enzyme inhibitor</keyword>
</DOC>